NEW YORK CITY — Patients with borderline personality disorder showed significant improvements when treated with long-acting antipsychotic agent quetiapine fumarate (Seroquel XR) in a placebo-controlled trial, a researcher said here. Scores on the Zanarini Rating Scale for borderline personality …

READ FULL ARTICLE Curated publisher From Medical Page Today